Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331051 | 0.81 | CA12 (0.51) | SMN1; SMN2POLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL20590864 | 0.81 | CA12 (0.54) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL31455595 | 0.80 | CYP4F2 (0.52) | SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL8114167 | 0.78 | CYP4F2 (0.52) | SMN1; SMN2RAB9ANPC1ALDH1A1L3MBTL1 | |
| SCHEMBL20590822 | 0.76 | GAA (0.48) | SMN1; SMN2RAB9ANPC1KMT2ALMNA | |
| SCHEMBL8115498 | 0.75 | TSHR (0.55) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL19277458 | 0.75 | POLB (0.61) | SMN1; SMN2POLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL28103785 | 0.74 | HPGD (0.61) | SMN1; SMN2POLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL397968 | 0.74 | CYP4F2 (0.51) | SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL29015042 | 0.74 | MAPT (0.53) | SMN1; SMN2RAB9ANPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | SMN1; SMN2 4769/4885POLB 4110/4885RAB9A 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.